Edwards Lifesciences (NYSE:EW) Price Target Raised to $100.00 at BTIG Research

Edwards Lifesciences (NYSE:EW) had its price objective upped by equities researchers at BTIG Research from $98.00 to $100.00 in a report issued on Friday,Benzinga reports. The brokerage presently has a “buy” rating on the medical research company’s stock. BTIG Research’s target price points to a potential upside of 25.48% from the stock’s current price.

A number of other analysts also recently commented on the company. TD Cowen upgraded Edwards Lifesciences from a “hold” rating to a “buy” rating in a report on Friday, January 9th. Robert W. Baird set a $90.00 price objective on Edwards Lifesciences in a report on Monday, January 12th. Weiss Ratings restated a “hold (c)” rating on shares of Edwards Lifesciences in a report on Monday. UBS Group restated a “neutral” rating and set a $94.00 price objective on shares of Edwards Lifesciences in a report on Wednesday, February 4th. Finally, Stifel Nicolaus set a $110.00 price objective on Edwards Lifesciences and gave the stock a “buy” rating in a report on Tuesday, January 20th. Three research analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and nine have given a Hold rating to the stock. According to data from MarketBeat, Edwards Lifesciences presently has an average rating of “Moderate Buy” and an average price target of $95.48.

Edwards Lifesciences Price Performance

EW opened at $79.69 on Friday. The company’s 50 day simple moving average is $81.54 and its 200 day simple moving average is $82.15. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.09 and a current ratio of 3.72. Edwards Lifesciences has a 1 year low of $72.30 and a 1 year high of $87.89. The stock has a market capitalization of $45.95 billion, a PE ratio of 43.55, a P/E/G ratio of 2.12 and a beta of 0.95.

Edwards Lifesciences (NYSE:EW) last released its quarterly earnings data on Thursday, April 23rd. The medical research company reported $0.78 EPS for the quarter, topping analysts’ consensus estimates of $0.73 by $0.05. The business had revenue of $1.65 billion during the quarter, compared to the consensus estimate of $1.60 billion. Edwards Lifesciences had a return on equity of 14.50% and a net margin of 17.69%.The business’s revenue for the quarter was up 16.7% on a year-over-year basis. During the same period in the prior year, the firm posted $0.64 EPS. Edwards Lifesciences has set its FY 2026 guidance at 2.950-3.050 EPS and its Q2 2026 guidance at 0.700-0.760 EPS. As a group, sell-side analysts expect that Edwards Lifesciences will post 2.96 EPS for the current year.

Insider Buying and Selling at Edwards Lifesciences

In other Edwards Lifesciences news, VP Daniel J. Lippis sold 1,019 shares of the firm’s stock in a transaction dated Monday, April 6th. The stock was sold at an average price of $80.98, for a total value of $82,518.62. Following the transaction, the vice president directly owned 33,934 shares of the company’s stock, valued at $2,747,975.32. This trade represents a 2.92% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Scott B. Ullem sold 13,000 shares of the firm’s stock in a transaction dated Thursday, April 9th. The shares were sold at an average price of $80.04, for a total value of $1,040,520.00. Following the completion of the transaction, the chief financial officer directly owned 39,699 shares in the company, valued at $3,177,507.96. This trade represents a 24.67% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 86,058 shares of company stock valued at $7,118,636 over the last three months. 0.31% of the stock is owned by company insiders.

Hedge Funds Weigh In On Edwards Lifesciences

A number of institutional investors have recently added to or reduced their stakes in EW. Hanson & Doremus Investment Management acquired a new position in Edwards Lifesciences in the 1st quarter worth $25,000. JPL Wealth Management LLC acquired a new position in Edwards Lifesciences in the 3rd quarter worth $25,000. MV Capital Management Inc. acquired a new position in Edwards Lifesciences in the 4th quarter worth $26,000. Kemnay Advisory Services Inc. acquired a new position in Edwards Lifesciences in the 4th quarter worth $27,000. Finally, True Wealth Design LLC lifted its holdings in Edwards Lifesciences by 251.5% in the 3rd quarter. True Wealth Design LLC now owns 362 shares of the medical research company’s stock worth $28,000 after buying an additional 259 shares in the last quarter. Institutional investors and hedge funds own 79.46% of the company’s stock.

More Edwards Lifesciences News

Here are the key news stories impacting Edwards Lifesciences this week:

• Positive Sentiment: Q1 top-line beat and strong surgical product demand—Revenue rose ~16.7% YoY to about $1.65B, led by robust demand for artificial/transcatheter heart valves, which analysts flagged as the quarter’s standout driver. Read More.
• Positive Sentiment: Profitability and cash flow improvement—The company reported better-than-expected quarterly EPS per several outlets and showed improved operating profit and operating cash flow, supporting margins and longer-term earnings power. Read More.
• Neutral Sentiment: Guidance mostly in line but with range risk—Q2 EPS guidance of $0.70–$0.76 and FY 2026 EPS of $2.95–$3.05 are roughly around consensus but leave room for variance, which can limit upside if execution slips. Read More.
• Neutral Sentiment: Analyst positioning remains constructive—Multiple buy/overweight ratings and a median 12-month target near $98 point to continued analyst confidence, which can support the stock if results remain steady. Read More.
• Negative Sentiment: Insider selling and potential profit-taking—Recent notable insider sales and the large post-earnings run-up increase the risk of near-term selling pressure. Read More.
• Negative Sentiment: Mixed datapoints and market reaction—Although headlines emphasized a beat, some outlets highlighted differing EPS metrics and the stock’s reversal from its post-earnings pop, suggesting investors are parsing nuances rather than celebrating a clear clean beat. Read More.

About Edwards Lifesciences

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.